Sistema de Salut de Catalunya
Institut Català de la Salut
[Higuera M] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Vargas-Accarino E, Bermúdez-Ramos M] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Torrens M, Soriano-Varela A] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Salcedo MT] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Instituto de salud Carlos III, Madrid, Spain. Department of Medicine, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Mínguez B] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-04-10T12:48:08Z
2025-04-10T12:48:08Z
2025-04
Carcinoma hepatocel·lular; Zinc; Biomarcador
Hepatocellular carcinoma; Zinc; Biomarker
Carcinoma hepatocelular; Zinc; Biomarcador
Background Zinc (Zn) is an essential trace element involved in a wide variety of cellular processes and is vital for optimal liver function. Our objective was to elucidate the potential therapeutic role of Zn in hepatocellular carcinoma (HCC), the third leading cause of cancer-related death and the first cause of death in patients with cirrhosis. Methods The impact of Zn supplementation on proliferation, invasion, migration, cell cycle, and apoptosis was conducted on four HCC cell lines as well as in a xenograft mouse model of HCC from which tumor gene expression profiles were also analyzed. Gene deregulation and protein expression were validated in human HCC tissues. Finally, Zn and MT1 (Metallothionein 1) levels were quantified in plasma from patients with HCC. Results Zn supplementation significantly modulated proliferation, invasion, and migration in HCC cell lines and induced apoptosis in a dose-dependent manner. Although Zn did not exhibit a significant increase in survival, Zn supplementation significantly altered the expression of MT genes. Specifically, MT1G and MT1H expression were notably suppressed in HCC tissues from mice and these results were validated in human HCC samples. Overall, gene and protein MTs expression was significantly lower in HCC areas compared to adjacent liver tissue and plasma Zn levels exhibited substantial variation across different stages of the liver disease. Conclusion Zn supplementation influences key cellular behaviors in a dose-dependent manner and upregulates the expression of MT family genes, which may have tumor-suppressive properties, in vitro an in vivo models. Future research should investigate the prognostic implications of Zn supplementation as part of a comprehensive therapeutic strategy for HCC patients.
This work has been funded by a research grant from Laboratorios Viñas. BM is supported by competitive funding by Instituto de Salud Carlos III (ISCIII) (PI18/00961 and PI21/00714) and co-funded by the European Union.
Article
Published version
English
Fetge - Càncer - Tractament; Rates (Animals de laboratori); Zinc - Ús terapèutic; Metal·loproteïnes; CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Metals, Heavy::Zinc; Other subheadings::Other subheadings::/pharmacology; DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ORGANISMS::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Eutheria::Rodentia::Muridae::Murinae::Mice; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Metalloproteins::Metallothionein; COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::metales pesados::zinc; Otros calificadores::Otros calificadores::/farmacología; ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ORGANISMOS::Eukaryota::animales::Chordata::vertebrados::mamíferos::Eutheria::Rodentia::Muridae::Murinae::ratones; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::metaloproteínas::metalotioneína
Elsevier
Biomedicine & Pharmacotherapy;185
https://doi.org/10.1016/j.biopha.2025.117918
info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F00714
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]
